 Merrimack Pharmaceuticals Inc said its treatment for advanced pancreatic cancer helped extend patients lives by nearly two months compared with a control group in a latestage study a statistically significant survival advantage in a condition where some patients live just a few months after diagnosis with advanced disease  Merrimack based in Cambridge Mass said it would seek regulatory approval for the drug called MM as a secondline treatment later this year It announced the results in a statement and said
  